...
首页> 外文期刊>Hormone and Metabolic Research >Is there visceral adipose tissue (VAT) intracellular hypercortisolism in human obesity?
【24h】

Is there visceral adipose tissue (VAT) intracellular hypercortisolism in human obesity?

机译:人肥胖症中是否存在内脏脂肪组织(VAT)细胞内皮质醇过多症?

获取原文
获取原文并翻译 | 示例
           

摘要

The fact that obesity is a prominent feature of Cushing's syndrome (systemic hypercortisolism of adrenocortical origin) stimulated a 40-year search for evidence of systemic hypercortisolism in human obesity. That search has failed to find such evidence. For the past 15 years, however, studies have been done to evaluate a possible alternative type of hypercortisolism in obesity, namely visceral adipose tissue (VAT) intracellular hypercortisolism. The current review summarizes the evidence published so far about this possibility. There have been three types of evidence studied: direct measurement of the VAT levels of 11β-hydroxysteroid dehydrogenase type I (11-HSD-1), which converts biologically inactive cortisone to biologically active cortisol; direct measurement of splanchnic cortisol production; and evaluation of the effect of a specific inhibitor of 11-HSD-1 on metabolic abnormalities associated with obesity, particularly diabetes mellitus. The results are complex and difficult to interpret. Our conclusion is that the presence of VAT intracellular hypercortisolism in human obesity is possible but unlikely.
机译:肥胖是库欣综合症(肾上腺皮质源性全身性皮质醇过多症)的突出特征,这一事实刺激了40年来对人类肥胖症中全身性皮质醇过多症证据的探索。该搜索未能找到此类证据。然而,在过去的15年中,已经进行了研究以评估肥胖症中可能的另一种类型的皮质醇过多症,即内脏脂肪组织(VAT)细胞内皮质醇过多症。本篇综述总结了迄今为止发表的有关这种可能性的证据。已经研究了三种类型的证据:直接测量I型11β-羟基类固醇脱氢酶(11-HSD-1)的增值税水平,该水平可将无生物活性的可的松转化为有生物活性的可的松;直接测量内脏皮质醇的产生;和评估11-HSD-1特异性抑制剂对与肥胖症相关的代谢异常(尤其是糖尿病)的作用。结果复杂且难以解释。我们的结论是,在人类肥胖症中存在VAT细胞内皮质醇增生是可能的,但不太可能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号